Steven T. Rosen Prof Cancer Bio Cncr ImmunoTx Co-lead @NUFeinbergMed @NorthwesternMed Dir. Sarcoma Prgm @LurieCancer #immunotherapy for #sarcoma #cures
Chicago, IL
Joined November 2018
- Tweets934
- Following631
- Followers1.5K
- Likes3.7K
Seth M. Pollack retweeted
Critical questions being addressed on the sarcoma panel at the #BGT2026 today led by @immunosarc with @JTrentMDPhD @VivekSubbiah addressing these -
Full house and robust dialogue
Seth M. Pollack retweeted
Northwestern Memorial Hospital is proud to be ranked No. 8 in the nation for cancer care by @USNews, 2026 – 2027, and home of Robert H. Lurie Comprehensive Cancer Center, rated “Exceptional” by the National Cancer Institute.
Thank you to our team for these achievements.
breakthroughsforphysicians.n…
Seth M. Pollack retweeted
In this episode of Better Edge, Oncologist Seth M. Pollack, MD (@immunosarc), discusses the evolving treatment landscape for #leiomyosarcoma and highlights clinical trial data recently published in @TheLancetOncol.
Dr. Pollack was co-author on the publication, which evaluated the combination of #cabozantinib, a multitargeted tyrosine kinase inhibitor, with #temozolomide in patients with refractory soft tissue sarcomas.
Listen here: youtube.com/watch?v=WmP1FiRA…
Seth M. Pollack retweeted
A 4-line standard has held for 6 years in advanced GIST. Now PEAK phase 3 data on bezuclastinib plus sunitinib is changing the conversation: PFS 16.5 vs 9.2 months (HR 0.50, P<.0001) and ORR nearly doubled. Sarcoma experts break down what comes next.
Watch the full episodes: hubs.li/Q04mnH2t0 (hubs.li/Q04mnCg50)
@JasonSicklick @UCSDsurgery @AgulnikMd @CityofHope @NeetaSomaiahMD @UTMDAnderson @immunosarc @NorthwesternMed #GIST #SarcomaSmSurg #PrecisionOncology
Seth M. Pollack retweeted
A look back at the 2026 SARC Semiannual Meeting at ASCO.
From groundbreaking research, clinical trial updates, and patient advocacy, this year's meeting showcased the power of collaboration in advancing sarcoma care.
Watch full meeting: youtube.com/playlist?list=PL…
#sarcoma #ASCO26
Seth M. Pollack retweeted
In this episode of Better Edge, Oncologist Seth M. Pollack, MD (@immunosarc), discusses the evolving treatment landscape for #leiomyosarcoma and highlights clinical trial data recently published in @TheLancetOncol.
Listen to the podcast here: breakthroughsforphysicians.n…
Seth M. Pollack retweeted
Two @NorthwesternMed #oncologists have been inducted into @the_asci, one of the oldest medical honor societies in the United States.
Mohamed Abazeed, MD, PhD (@theabzlab), specializes in #ThoracicCancers, and his research is focused on developing data-driven tools to personalize and improve #CancerTreatment.
Seth M. Pollack, MD (@immunosarc), conducts pioneering translation research that aims to overcome resistance to #TcellBasedTherapies.
Congratulations to Dr. Abazeed and Dr. Pollack on earning this prestigious distinction.
lnkd.in/e5esJcq8
Seth M. Pollack retweeted
Be sure to listen to the new podcast Rise to Face the Sun: The Patient Experience. Episodes 1 & 2 out now!
Spotify: open.spotify.com/show/2mKNIK…
#sarcoma #patientexperience #podcast #sarcomaawareness
Seth M. Pollack retweeted
Rise to Face the Sun: The Patient Experience debuts May 29th!
First we meet Eli Galloway who shares his fight against recurrent synovial #sarcoma — from #chemotherapy and amputation to engineered T-cell therapy, resilience, and survival.
#RareCancer #SarcomaAwareness
Seth M. Pollack retweeted
New #SARCTalk featuring Daphne Edgren — creator of the new podcast Rise to Face the Sun: The Patient Experience with #SARCTrials.
We talk patient storytelling, empathy in #healthcare, and the new #podcast premiering May 29, 2026.
Listen Now: open.spotify.com/episode/1OA…
#sarcoma
Seth M. Pollack retweeted
"These findings support the combination as a potential treatment option for patients with advanced #leiomyosarcoma and provide a strong rationale for further study aimed at improving outcomes in this difficult-to-treat #cancer," said Seth Pollack, MD (@immunosarc), co-author of the study published in @TheLancetOncol.
Read moer: msn.com/en-us/health/other/c…
Seth M. Pollack retweeted
“It’s a tremendous honor to be part of such a historic and prestigious organization. @the_asci has long been home to physician-scientists who have fundamentally changed the way we understand and treat disease, and I’m deeply grateful to join their ranks,” said Seth M. Pollack, MD (@immunosarc), who is also a co-leader of the #CancerImmunology and #Immunotherapy Initiative at @LurieCancer.
Read more: news.feinberg.northwestern.e…
#SarcomaImmunobiology
I’m pleased to be speaking at the MOSS 2026 Symposium in Miami (Jan 22–23, 2026). Looking forward to joining colleagues for two days focused on advances in musculoskeletal oncology and sarcoma. More information and registration: moss.cme-congresses.com/regi…
We are looking for another #sarcoma medical oncologist!!!! Please reach out to me if you or some one you know is interested!!!!
Seth M. Pollack retweeted
Excited to be on a #Sarcoma panel with Seth Pollock @immunosarc @DanielOlsonMD Bruce Brockstein at the BGT Biomarkers, Genes and Targets Conference in #Chicago @chadinabhan
precisca.com/hubfs/Events/Ch…
Seth M. Pollack retweeted
.@immunosarc of @LurieCancer is leading EA7222, a randomized phase 3 trial of doxorubicin alone or in combination with pembrolizumab in patients with advanced UPS and related poorly differentiated #sarcomas. More here: bit.ly/EA7222 cc: @CureSarcoma
Seth M. Pollack retweeted
.@immunosarc of @LurieCancer is leading EA7222, a randomized phase 3 trial of doxorubicin alone or in combination with pembrolizumab in patients with advanced UPS and related poorly differentiated #sarcomas. More here: bit.ly/EA7222 cc: @CureSarcoma
Seth M. Pollack retweeted
#ClinicalTrial EA7222, led by @immunosarc of @LurieCancer, is a randomized phase 3 trial of doxorubicin alone or in combination w/ pembrolizumab for patients w/ advanced soft tissue #sarcoma & related poorly differentiated sarcomas that are unresectable. bit.ly/EA7222
